Ascentage Pharma to Showcase 17 Clinical Data Sets at EHA2026
Event summary
- Ascentage Pharma will present 17 clinical advances at the 31st European Hematology Association Congress (EHA2026) in Stockholm, Sweden, from June 11 to 14, 2026.
- The presentations include 8 poster sessions featuring data on Olverembatinib (HQP1351) and Lisaftoclax (APG-2575).
- Key abstracts cover updated efficacy and safety data for Olverembatinib in chronic-phase chronic myeloid leukemia (CP-CML) and efficacy in patients with prior resistance to other treatments.
- Lisaftoclax's data includes correlation of baseline characteristics with prognosis in CLL/SLL patients and safety and preliminary efficacy in pediatric patients with relapsed/refractory Ph+ ALL.
The big picture
Ascentage Pharma's presentation of 17 clinical advances at EHA2026 underscores its focus on advancing innovative therapies for hematologic malignancies. The company's strategic partnerships with leading biotechnology and pharmaceutical firms, along with its robust R&D capabilities, position it to capitalize on the growing demand for targeted cancer treatments. The upcoming data presentations could significantly influence the regulatory and commercial trajectory of its key assets, Olverembatinib and Lisaftoclax.
What we're watching
- Regulatory Approvals
- Whether Olverembatinib and Lisaftoclax will secure FDA approvals following the positive clinical data presented at EHA2026.
- Market Expansion
- The pace at which Ascentage Pharma can expand the commercialization of its approved products in global markets.
- Clinical Trial Progress
- How the ongoing registrational Phase III trials for Olverembatinib and Lisaftoclax will impact the company's pipeline and market position.
Related topics